Paradigm Biopharmaceuticals PBIGF Stock
Paradigm Biopharmaceuticals Price Chart
Paradigm Biopharmaceuticals PBIGF Financial and Trading Overview
Paradigm Biopharmaceuticals stock price | 0.38 USD |
Previous Close | 0.61 USD |
Open | 0.61 USD |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.61 - 0.61 USD |
52 Week Range | 0.61 - 1.36 USD |
Volume | 144 USD |
Avg. Volume | 517 USD |
Market Cap | 172.36M USD |
Beta (5Y Monthly) | 1.140996 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.03 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
PBIGF Valuation Measures
Enterprise Value | 88.91M USD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 4449.8228 |
Price/Book (mrq) | 2.340996 |
Enterprise Value/Revenue | 2295.414 |
Enterprise Value/EBITDA | -1.669 |
Trading Information
Paradigm Biopharmaceuticals Stock Price History
Beta (5Y Monthly) | 1.140996 |
52-Week Change | -22.68% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.36 USD |
52 Week Low | 0.61 USD |
50-Day Moving Average | 0.68 USD |
200-Day Moving Average | 0.91 USD |
PBIGF Share Statistics
Avg. Volume (3 month) | 517 USD |
Avg. Daily Volume (10-Days) | 0 USD |
Shares Outstanding | 282.09M |
Float | 240.52M |
Short Ratio | N/A |
% Held by Insiders | 16.46% |
% Held by Institutions | 19.20% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -137597.26% |
Gross Margin | -107.73% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -42.70% |
Return on Equity (ttm) | -69.72% |
Income Statement
Revenue (ttm) | 38.73K USD |
Revenue Per Share (ttm) | 0 USD |
Quarterly Revenue Growth (yoy) | -89.60% |
Gross Profit (ttm) | -64527 USD |
EBITDA | -53284852 USD |
Net Income Avi to Common (ttm) | -44131976 USD |
Diluted EPS (ttm) | -0.11 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 83.93M USD |
Total Cash Per Share (mrq) | 0.3 USD |
Total Debt (mrq) | 389.78K USD |
Total Debt/Equity (mrq) | 0.53 USD |
Current Ratio (mrq) | 5.892 |
Book Value Per Share (mrq) | 0.261 |
Cash Flow Statement
Operating Cash Flow (ttm) | -33231114 USD |
Levered Free Cash Flow (ttm) | -22377408 USD |
Profile of Paradigm Biopharmaceuticals
Country | United States |
State | VIC |
City | Melbourne |
Address | 500 Collins Street |
ZIP | 3000 |
Phone | 61 3 9629 5566 |
Website | https://www.paradigmbiopharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Paradigm Biopharmaceuticals Limited, a drug repurposing company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Q&A For Paradigm Biopharmaceuticals Stock
What is a current PBIGF stock price?
Paradigm Biopharmaceuticals PBIGF stock price today per share is 0.38 USD.
How to purchase Paradigm Biopharmaceuticals stock?
You can buy PBIGF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Paradigm Biopharmaceuticals?
The stock symbol or ticker of Paradigm Biopharmaceuticals is PBIGF.
Which industry does the Paradigm Biopharmaceuticals company belong to?
The Paradigm Biopharmaceuticals industry is Biotechnology.
How many shares does Paradigm Biopharmaceuticals have in circulation?
The max supply of Paradigm Biopharmaceuticals shares is 389.43M.
What is Paradigm Biopharmaceuticals Price to Earnings Ratio (PE Ratio)?
Paradigm Biopharmaceuticals PE Ratio is now.
What was Paradigm Biopharmaceuticals earnings per share over the trailing 12 months (TTM)?
Paradigm Biopharmaceuticals EPS is -0.03 USD over the trailing 12 months.
Which sector does the Paradigm Biopharmaceuticals company belong to?
The Paradigm Biopharmaceuticals sector is Healthcare.